[Newsmp] Pfizer Pharmaceutical Korea's atopic dermatitis treatment Cibinqo, Kyowa Kirin Korea's hyperphosphatemia treatment Nephoxil, and Novartis Korea's chronic myelogenous leukemia treatment Scemblix were newly listed on the list of drug benefits.
Among the existing listed items, Ultomiris (AstraZeneca Korea) and Verassil (Johnson & Johnson MedTech Korea) will be newly included with additional dosage options.
Moreover, the reimbursement cap for Opsumit (Janssen Korea) will be decreased by 30%, and the removal of the two Madopar (Roche Korea) items from the list, which was originally planned, will be postponed until December 31.
The Ministry of Health and Welfare released a notice reflecting these updates in the Amendment of the drug benefits list and the maximum benefit amount table on 27. The effective date of these changes will be the 1st of next month (July).
According to the announcement, the reimbursement ceiling for Nephoxil Cap. 500mg is set at KRW 377 per capsule, while Scemblix is priced at KRW 59,140 per tablet for the 20mg dosage and KRW 76,371 per tablet for the 40mg dosage.
Cibinqo has been listed with a maximum reimbursement amount of KRW 11,087 per tablet for the 50mg dosage, KRW 17,739 per tablet for the 100mg dosage, and KRW 25,942 per tablet for the 200mg dosage.
Verassil Prefilled Syringe Kit, in addition to the existing 2ml, will be newly included with a 4ml option priced at KRW 269,509. Ultomiris Inj. 100mg/ml will have an additional 3ml option per vial priced at KRW 5,598,942, while the newly included 11ml option per vial will be set at KRW 19,036,403.
The four available dosages of Strensiq Inj. have been newly included, with a supplier switch from Handok to AstraZeneca Korea.
The upper limit for Opsumit Tab. 10mg, an existing item, will be reduced by 30.0% from KRW 48,512 to KRW 33,958, and an additional reduction of 23.5% will be applied starting from June 1 next year.
Furthermore, the reimbursement ceiling for Atmeg Combigel Soft Cap. (Korea United Pharmaceutical) will be reduced by 21.2% from KRW 1,219 to KRW 960, while Kukje Pharma's Cholencina Soft Cap. and Chlencia Tab. will each be retreated by 10.2% from KRW 522 to KRW 469.
Tacroli will undergo a 9.9% reduction from KRW 2,868 to KRW 2,584 per capsule, while Tacroli Cap. 0.5mg (Reyon Pharmaceutical) will see a 20.3% decrease from KRW 2,121 to KRW 1,691 per capsule.
Trulicity (Lilly) will have a 4.4% price reduction from KRW 19,226 to KRW 18,382 per pen for the 0.75mg dosage and a 1.7% reduction from KRW 31,181 to KRW 30,666 per pen for the 1.5mg dosage.
Entresto Film Coated Tab. (Novartis) is reduced by 1.0% from KRW 1,792 to KRW 1,774 for all three doses of 50 mg, 100 mg, and 200 mg.
On the other hand, the upper limit for Succicholine Inj. 50mg/mL (Ilsung Pharmaceutical) will be increased by 25.5% from KRW 910 to KRW 1,142 per 2ml ample, while Jeil Pethidine HCl Inj. will see a 25.2% rise from KRW 314 to KRW 393 per 50mg/1ml ample and an 11.0% increase from KRW 283 to KRW 314 per 25mg/0.5ml ample.
Forus Eye Drops (Samil Pharmaceutical) will have a 14.3% price increase from KRW 1,309 to KRW 1,496 per 10ml vial, Megesia (Dalim Biotech) an 8.9% increase from KRW 471 to KRW 513 per tablet, and Celltrion Oxymetolone (Celltrion Pharm) a 2.5% increase from KRW 710 to KRW 728 per tablet.
